TTFC

AcronymDefinition
TTFCTime to First Cigarette (addiction research)
TTFCToken Test for Children (screening test)
TTFCTrail to First Class (Boy Scouts)
TTFCTaking Total Financial Control
TTFCTactical and Technical Fire Control
TTFCTachypleus Tridentatus Factor C (biochemistry)
References in periodicals archive ?
The approved formulation of TTFC in Argentina, Australia, and Korea is DuoTrav PQ[R] (with polyquad as preservative) and in Mexico and Russia is DuoTrav BAK[R] (with benzalkonium chloride as preservative).
IOP between TTFC and beta-blocker monotherapy at week 4.
IOP at week 4 (IOP in TTFC group lower than IOP in beta-blocker group) if the true difference was >1.5 mmHg between treatments based on the assumption of a standard deviation (SD) of 3.5 mmHg and the use of a two-sample, one-sided t-test performed at a = 0.05 level of significance.
For the superiority hypothesis, TTFC treatment was considered superior to beta-blocker monotherapy if the least squares means (LSM) difference in the mean 8 a.m.
The baseline and demographic characteristics were similar between the TTFC and beta-blocker groups (Table 1).
The mean IOP ([+ or -]SD) in the TTFC and beta-blocker groups was 22.5 ([+ or -]2.5) mmHg and 22.2 ([+ or -]2.3) mmHg, respectively, at baseline.
IOP was lower in the TTFC group (16.7 [+ or -] 3.1 mmHg) than in the beta-blocker group (21.2 [+ or -] 3.1 mmHg).
IOP were greater in the TTFC group compared with the betablocker group (p < 0.0001; Figures 3(a) and 3(b)).
IOP after 4 weeks of treatment with TTFC (mean change: -3.5 [+ or -] 3.9 mmHg; percentage change: -15.3% [+ or -]16.6%).
Among patients receiving TTFC treatment for 8 weeks, the mean change in 8 a.m.
Although direct comparisons to the present study are difficult, studies involving patients with a mean pretherapy pressure of 22-24 mmHg have reported a 31-34% decrease in intraocular pressure with LTFC [15,16] and a 31-32% decrease with TTFC [17,18].
Latanoprost/LTFC Travoprost/TTFC Case number 13 14 Gender (male/female) 7/6 8/6 Age 64.0 [+ or -] 6.5 53.4 [+ or -] 7.6 Baseline IOP with GAT (mmHg) 17.6 [+ or -] 17.6 [+ or -] 1.35 1.21 Latanoprost LTFC Spherical equivalent (diopter) -4.88 [+ or -] -5.00 [+ or -] 2.5 3.2 MD score (HFA30/24-2) -3.91 [+ or -] -9.34 [+ or -] 4.13 5.0 Travoprost/TTFC Case number Gender (male/female) Age Baseline IOP with GAT 17.4 [+ or -] 17.4 [+ or -] (mmHg) 2.00 1.86 Travoprost TTFC Spherical equivalent -6.69 [+ or -] -6.89 [+ or -] (diopter) 4.07 4.03 -3.51 [+ or -] -7.12 [+ or -] MD score (HFA30/24-2) 4.27 3.24 IOP: intraocular pressure.